FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3185127523> ?p ?o ?g. }

• W3185127523 endingPage "831" @default.
• W3185127523 startingPage "824" @default.
• W3185127523 abstract "Breast cancer stem cells (BCSCs) have been proven to be the root of development, metastasis and recurrence of breast cancer. It is crucial to explore the underlying paths of regulating BCSCs for breast cancer treatment. Many bioactive materials have been developed to modify therapeutic drugs or as drug delivery vehicles for tumor treatment. In this study, we aimed to probe the effect of microRNA-7 (miR-7) agomir, a potential bioactive material, in breast cancer treatment by reducing tumorigenicity of BCSCs. Magnetic activated cell sorting was used to isolate the BCSCs from the MDA-MB-231 and LD cells. Protein array was performed to screen differentially expressed proteins. The expression levels for miR-7 and CD44 in human breast cancer cell lines were detected by Quantitative real-time PCR (q-PCR), Western blot (WB) and Flow cytometry (FCM) assays. Lentiviral recombinants were constructed to infect the primary human breast cancer cells to obtain the cells stably overexpressing miR-7. BCSCs xenograft model was established in NOD/SCID mice and the tumor tissues were analyzed by hematoxylin-eosin staining (HE) and immunohistochemistry (IHC). We found that miR-7 agomir can inhibit the tumor growth in mice and the expression of CD44 in the tumor tissues treated with miR-7 agomir was 2.4 times lower than that of control treatment from the protein array results. Among the MDA-MB- 231, MCF-7, SK-BR-3 and LD human breast cancer cell lines, the expression of CD44 was downregulated in the MCF-7 cells with relatively high miR-7 expression. Overexpression of miR-7 effectively reduced the CD44 expression in LD cells. Furthermore, compared with control and chemotherapy treatments, the mouse tumor growth was significantly inhibited in the mice infected with Lenti-miR-7-BCSCs, concomitantly decreasing the CD44 expression in tumor tissues. These findings suggest that miR-7 agomir can be used as a potential bioactive material to inhibit tumor growth in BCSCs xenograft mouse model by downregulating the CD44 expression and reducing BCSCs tumorigenicity." @default.
• W3185127523 created "2021-08-02" @default.
• W3185127523 creator A5037824528 @default.
• W3185127523 creator A5051466221 @default.
• W3185127523 creator A5061407463 @default.
• W3185127523 creator A5065009308 @default.
• W3185127523 creator A5081685869 @default.
• W3185127523 date "2021-06-01" @default.
• W3185127523 modified "2023-09-26" @default.
• W3185127523 title "MicroRNA-7 agomir is a potential bioactive material for breast cancer therapy by inhibiting breast cancer stem cell tumorigenicity" @default.
• W3185127523 cites W1829348795 @default.
• W3185127523 cites W1964962769 @default.
• W3185127523 cites W1980982863 @default.
• W3185127523 cites W2116455112 @default.
• W3185127523 cites W2128627710 @default.
• W3185127523 cites W2144402328 @default.
• W3185127523 cites W2161662910 @default.
• W3185127523 cites W2568928303 @default.
• W3185127523 cites W2805893461 @default.
• W3185127523 cites W2806713886 @default.
• W3185127523 cites W2891743556 @default.
• W3185127523 cites W2904346898 @default.
• W3185127523 cites W2920921684 @default.
• W3185127523 cites W2922330509 @default.
• W3185127523 cites W2923574624 @default.
• W3185127523 cites W2968153232 @default.
• W3185127523 cites W2970757780 @default.
• W3185127523 cites W2978198262 @default.
• W3185127523 cites W2987828248 @default.
• W3185127523 cites W2991295720 @default.
• W3185127523 cites W2997182655 @default.
• W3185127523 cites W3081851111 @default.
• W3185127523 cites W3093930855 @default.
• W3185127523 doi "https://doi.org/10.1166/mex.2021.2001" @default.
• W3185127523 hasPublicationYear "2021" @default.
• W3185127523 type Work @default.
• W3185127523 sameAs 3185127523 @default.
• W3185127523 citedByCount "1" @default.
• W3185127523 countsByYear W31851275232023 @default.
• W3185127523 crossrefType "journal-article" @default.
• W3185127523 hasAuthorship W3185127523A5037824528 @default.
• W3185127523 hasAuthorship W3185127523A5051466221 @default.
• W3185127523 hasAuthorship W3185127523A5061407463 @default.
• W3185127523 hasAuthorship W3185127523A5065009308 @default.
• W3185127523 hasAuthorship W3185127523A5081685869 @default.
• W3185127523 hasConcept C104317684 @default.
• W3185127523 hasConcept C111683008 @default.
• W3185127523 hasConcept C118646709 @default.
• W3185127523 hasConcept C121608353 @default.
• W3185127523 hasConcept C125473707 @default.
• W3185127523 hasConcept C126322002 @default.
• W3185127523 hasConcept C145059251 @default.
• W3185127523 hasConcept C1491633281 @default.
• W3185127523 hasConcept C153911025 @default.
• W3185127523 hasConcept C203014093 @default.
• W3185127523 hasConcept C204232928 @default.
• W3185127523 hasConcept C2776415932 @default.
• W3185127523 hasConcept C2779013556 @default.
• W3185127523 hasConcept C2780932548 @default.
• W3185127523 hasConcept C28328180 @default.
• W3185127523 hasConcept C502942594 @default.
• W3185127523 hasConcept C530470458 @default.
• W3185127523 hasConcept C54355233 @default.
• W3185127523 hasConcept C553184892 @default.
• W3185127523 hasConcept C55427017 @default.
• W3185127523 hasConcept C55493867 @default.
• W3185127523 hasConcept C71924100 @default.
• W3185127523 hasConcept C86803240 @default.
• W3185127523 hasConcept C95444343 @default.
• W3185127523 hasConceptScore W3185127523C104317684 @default.
• W3185127523 hasConceptScore W3185127523C111683008 @default.
• W3185127523 hasConceptScore W3185127523C118646709 @default.
• W3185127523 hasConceptScore W3185127523C121608353 @default.
• W3185127523 hasConceptScore W3185127523C125473707 @default.
• W3185127523 hasConceptScore W3185127523C126322002 @default.
• W3185127523 hasConceptScore W3185127523C145059251 @default.
• W3185127523 hasConceptScore W3185127523C1491633281 @default.
• W3185127523 hasConceptScore W3185127523C153911025 @default.
• W3185127523 hasConceptScore W3185127523C203014093 @default.
• W3185127523 hasConceptScore W3185127523C204232928 @default.
• W3185127523 hasConceptScore W3185127523C2776415932 @default.
• W3185127523 hasConceptScore W3185127523C2779013556 @default.
• W3185127523 hasConceptScore W3185127523C2780932548 @default.
• W3185127523 hasConceptScore W3185127523C28328180 @default.
• W3185127523 hasConceptScore W3185127523C502942594 @default.
• W3185127523 hasConceptScore W3185127523C530470458 @default.
• W3185127523 hasConceptScore W3185127523C54355233 @default.
• W3185127523 hasConceptScore W3185127523C553184892 @default.
• W3185127523 hasConceptScore W3185127523C55427017 @default.
• W3185127523 hasConceptScore W3185127523C55493867 @default.
• W3185127523 hasConceptScore W3185127523C71924100 @default.
• W3185127523 hasConceptScore W3185127523C86803240 @default.
• W3185127523 hasConceptScore W3185127523C95444343 @default.
• W3185127523 hasIssue "6" @default.
• W3185127523 hasLocation W31851275231 @default.
• W3185127523 hasOpenAccess W3185127523 @default.
• W3185127523 hasPrimaryLocation W31851275231 @default.
• W3185127523 hasRelatedWork W1616773284 @default.

• next